

Review Article

The Role of Pneumococcal Virulence Factors in Ocular Infectious Diseases

Angela H. Benton  and Mary E. Marquart 

Department of Microbiology and Immunology, University of Mississippi Medical Center, Jackson, MS 39216, USA

Correspondence should be addressed to Angela H. Benton; aahollis@umc.edu

Received 3 October 2018; Accepted 7 November 2018; Published 13 November 2018

Academic Editor: Eric G. Romanowski

Copyright © 2018 Angela H. Benton and Mary E. Marquart. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Streptococcus pneumoniae is a gram-positive, facultatively anaerobic pathogen that can cause severe infections such as pneumonia, meningitis, septicemia, and middle ear infections. It is also one of the top pathogens contributing to bacterial keratitis and conjunctivitis. Though two pneumococcal vaccines exist for the prevention of nonocular diseases, they do little to fully prevent ocular infections. This pathogen has several virulence factors that wreak havoc on the conjunctiva, cornea, and intraocular system. Polysaccharide capsule aids in the evasion of host complement system. Pneumolysin (PLY) is a cholesterol-dependent cytolysin that acts as pore-forming toxin. Neuraminidases assist in adherence and colonization by exposing cell surface receptors to the pneumococcus. Zinc metalloproteinases contribute to evasion of the immune system and disease severity. The main purpose of this review is to consolidate the multiple studies that have been conducted on several pneumococcal virulence factors and the role each plays in conjunctivitis, keratitis, and endophthalmitis.

1. Introduction

Streptococcus pneumoniae (*S. pneumoniae*) is a gram-positive, facultatively anaerobic pathogen responsible for many severe infections in different body sites [1]. *S. pneumoniae* frequently colonizes the nasopharynx of healthy adults [1, 2]. While many healthy adults asymptotically carry this bacterium, it is a leading cause of severe diseases such as pneumonia, meningitis, septicemia, and middle ear infections [3, 4]. *S. pneumoniae* continues to be one of the main causes for infectious diseases of the ocular surface such as keratitis and conjunctivitis, along with coagulase-negative *Staphylococcus*, *Staphylococcus aureus*, and *Pseudomonas aeruginosa* [5–9]. The following review will cover (A) three pneumococcal ocular infectious diseases: conjunctivitis, keratitis, and endophthalmitis and (B) the role specific pneumococcal virulence factors play in pathogenesis during each infection.

S. pneumoniae has many virulence factors including a polysaccharide capsule, pneumolysin, neuraminidases, and zinc metalloproteinases, all of which contribute to the severity of ocular infections [10]. The pneumococcal capsule aids in the evasion of the host complement system by reducing

both IgG and C-reactive protein binding [10–12]. Since *S. pneumoniae* avoids activating the complement system, it is less likely to be phagocytosed by neutrophils [13]. Both pneumococcal vaccines currently approved for use cover the most common pneumococcal serotypes involved in pneumonia and invasive diseases by targeting the capsule [14]; however, nonencapsulated *S. pneumoniae* (NESp) are the cause of most cases of conjunctivitis [15, 16]. There are two classification of NESp. Group I has the capsule polysaccharide biosynthetic (*cps*) locus but does not produce capsule due to a mutation or deletion [17, 18]. Group II does not have these *cps* genes but instead has novel oligopeptide binding proteins *aliC*, *aliD*, and/or the putative adhesin *pspK* [17, 19, 20]. Conjunctivitis strains have been identified as belonging to a subset clade of Group II which harbor *aliC* and *aliD* but not *pspK* [19].

When grown to stationary phase *in vitro*, *S. pneumoniae* spontaneously undergo self-lysis [21–23]. LytA, the main autolysin of *S. pneumoniae*, is indicated as an important virulence factor in several disease models [24–27]. There are 3 hypotheses for the mechanism behind the contribution of LytA to pneumococcal virulence. One theory suggests LytA is released by competent pneumococcal cells to lyse

noncompetent pneumococcal cells in the same environment [28]. This would allow for easy DNA exchange and integration by the naturally competent cells. A second hypothesis proposed that autolysis is induced to interfere with the cascade of host mediated immune responses [22, 29]. Phagocytosis of intact pneumococcal as well as phagocytostimulating cytokines is significantly reduced by autolyzed pneumococci [29]. Another suggestion for pneumococcal self-lysis is that lysis is induced to release other virulence factors, such pneumolysin [30]. Pneumolysin (PLY) is one of the most widely studied pneumococcal virulence factors. It has a damaging effect in every type of ocular infection covered in this review [31–38]. PLY is a cholesterol-dependent cytolysin that functions as a pore-forming toxin [38, 39]. This family of cytolysins also includes perfringolysin, streptolysin, and listeriolysin [39]. In addition to its cytolytic activity, PLY binds the Fc region of antibodies, which leads to a cascade of host mediated inflammation by activating the classical complement pathway [11, 40]. In some cases, PLY alone can cause as much damage alone as the bacteria producing it due to the massive immune response from the host.

In order to cause systemic disease, pneumococcus must first be able to colonize the nasopharynx [20, 41]. *S. pneumoniae* produces 3 neuraminidases (Nan), NanA, NanB, and NanC that assist in adherence and colonization [42–44]. Both NanA and NanB function as sialidases, exposing cell surface receptors to pneumococcus [10, 42]. Adherence and colonization are less likely to happen without the appropriate cell surface receptors being exposed by the neuraminidases; thus, disease states are also less likely to be established. Once a systemic infection is established, *S. pneumoniae* can become an invasive disease due to hyaluronate lyase [10]. Hyaluronate lyase belongs to a family of enzymes known as hyaluronidases [45]. These enzymes function as a virulence factors by breaking down the extracellular matrix components and increasing tissue permeability [46]. *S. pneumoniae* hyaluronate lyase cleaves the 1,4-glycosidic linkage in hyaluronan between the N-acetyl- β -d-glucosamine and d-glucuronic acid residues [47]. Hyaluronan has been found as component of the extracellular matrix in every tissue and fluid of both humans and animals [10, 45]. Cleavage of hyaluronan during an infection implicates hyaluronate lyase as a potential pneumococcal virulence factor that promotes tissue invasion.

S. pneumoniae produces three zinc metalloproteinases (Zmp), IgA1 protease, ZmpB, and ZmpC [48]. IgA1 protease cleaves neutralizing IgA1 antibodies at the hinge region [49]. Also, the pneumococcal production of IgA1 protease is necessary for bacterial adherence to epithelial cells [50]. ZmpB has been found in every isolated strain of *S. pneumoniae* [51, 52]. ZmpB causes an increase in tumor necrosis factor- α (TNF- α) concentration, which can exacerbate the severity of pneumococcal pneumonia and septicemia [53]. ZmpC can cleave host metalloproteinase-9 (MMP-9) and cause the removal of mucins from epithelial cells [54, 55]. Additionally, ZmpC binds to P-selectin and effectively inhibits neutrophil migration [56], as the binding of P-selectin to PSGL-1 neutrophil migration [57]. These zinc metalloproteinases not only contribute to evasion of the immune system but also the progression of serious pneumococcal diseases.

2. Infectious Diseases

2.1. Conjunctivitis. Approximately 1.35% of conjunctival infections are caused by bacteria [58], while allergens and viruses are more common culprits [59]. Even though bacterial conjunctival infections are less common, the indirect and direct costs of treatment is estimated to total over \$500,000,000 in the United States [58]. Typical infections are associated with redness, edema, purulent discharge [60], and occasionally light sensitivity [6, 61]. The most common bacterial pathogens isolated in adult conjunctival infections are the staphylococcal species [62]; however, conjunctivitis in children is more often caused by *Haemophilus influenzae*, *S. pneumoniae*, and *Moraxella catarrhalis* [59, 62]. *Neisseria gonorrhoeae* is commonly the isolated pathogen in cases of hyperacute bacterial conjunctivitis, which presents with swelling of the eyelid, pain, and purulent discharge [59, 63]. Pneumococcal conjunctival infections can be caused by poor contact lens hygiene, contaminated cosmetics, or living in close contact with others (military barracks, college dormitories, etc.) [16, 64]. While these infections are painful, they are treatable with topical antibiotics [65]. Patients receiving proper treatment for bacterial conjunctivitis recover with little to no vision loss [66].

The pneumococcal capsule, a well-studied virulence factor, is unnecessary for infection in the rabbit conjunctivitis model [7]. While both encapsulated and NESp have been isolated from patients with conjunctival infections, it is more often caused by the nontypeable strains of pneumococcus [7, 15, 16, 64, 67]. In a 2014 study, Valentino *et al.* collected 271 *S. pneumoniae* conjunctivitis isolates during clinical treatment. They determined through multilocus sequence typing that over 90% were nonencapsulated [15]. It is important to note that several NESp isolates have been isolated during conjunctival outbreaks [20, 64, 68]. Until recently it was thought that NESp was unlikely to cause diseases other than conjunctivitis [20, 69]. A recent publication by Bradshaw *et al.* showed the novel NESp oligopeptide *aliD* to be instrumental for production of cytolytic levels of pneumolysin in a virulent strain (MNZ41) [70]. The same study shows adhesion and colonization to be significantly higher in NESp strains containing both *aliC* and *aliD* [70]. This recent study by Bradshaw *et al.* clearly show the potential NESp has to cause disease, especially NESp that contain *aliC* and *aliD* such as the epidemic conjunctivitis strains of NESp [15].

Though capsule is not necessary, pneumococcal neuraminidase activity increases in the absence of capsule during conjunctivitis [7, 52]. In fact, at 3 and 12 hours after infection a capsule-deficient mutant exhibited significantly more neuraminidase activity than the parent strain in a rabbit conjunctivitis model [7]. Also, nonencapsulated pneumococcal conjunctivitis isolates produce significantly higher neuraminidase activity after 6 hours of bacterial exposure to higher mucin-expressing corneal epithelial cells [68].

Conjunctivitis strains of NESp, as well as encapsulated strains, also secrete a zinc metalloproteinase (ZmpC) that causes enhanced bacterial internalization by removing of specific mucins from the epithelium [55]. Mucins are proteins, and depending on their molecular structure, can be

either secreted or membrane-associated [71, 72]. Mucin 16 (MUC16) is part of the ocular surface glycocalyx and is also thought to provide a barrier to the epithelial surface [73, 74]. The removal of MUC16 by ZmpC, allows the pneumococcus to adhere and subsequently invade human conjunctival epithelial cells significantly better than the same strain lacking ZmpC [55]. ZmpC also cleaves human matrix metalloproteinase 9 (MMP-9), which is a key player in wound repair of epithelium [54, 75]. MMP-9 is upregulated in the eye by inflammatory cytokines TNF- α and interleukin-1-beta (IL1 β) during a disease state or microbial infection [76–78]. With the ability to remove MUC16 from the conjunctival epithelium and cleave MMP-9 [55], an infection with a ZmpC-producing strain increases the chance of a more severe pneumococcal infection.

2.2. Keratitis. Keratitis caused by pneumococcus can lead to corneal scarring, which can result in permanent visual reduction [66]. Infections are commonly caused by improper contact lens wear, trauma, or previous ocular surgery [79–81]. *S. pneumoniae* has been identified as one of the major agents of bacterial keratitis along with *Staphylococcus aureus* and *Pseudomonas aeruginosa* [82–84]. An analysis of bacterial keratitis cases over a 5-year span in one hospital showed *S. pneumoniae* was responsible for 38% of infections, *P. aeruginosa* for 29%, and *S. aureus* for 4% [85]. Other analyses of etiologic agents causing bacterial keratitis indicate similar distribution among pathogens [86, 87]. Improper keratitis treatment can lead to corneal ulcers [7, 66]. This ulceration of the cornea can result in a penetrating wound and lead to endophthalmitis [88]. Current treatment of bacterial keratitis consists of topical broad spectrum antibiotics [87, 89]; however, antibiotics alone may not be the most effective treatment since the pathogenesis during pneumococcal keratitis is not from bacterial burden alone [90].

The polysaccharide capsule of *S. pneumoniae* and PLY have been investigated for their roles in the progression of keratitis [7, 9, 34, 35]. Using the rabbit keratitis model, one study compared bacterial burden and infectivity of Avery's strain, a well-characterized encapsulated strain, and R6, the nonencapsulated strain [9]. Reed and colleagues showed no significant difference at 20 hours in bacterial burden or disease severity based on biomicroscopy examination. At 48 hours after infection, they recovered significantly more bacteria from corneas inoculated with Avery's encapsulated strain than with the nonencapsulated strain. The rabbits cleared the nonencapsulated strain more quickly than the encapsulated strain, but not before the host mediated inflammatory reactions caused damage to the corneas. This finding indicated that capsule was not necessary for pathogenesis as there was no significance difference in the biomicroscopy scores.

The host reaction to PLY causes much of the inflammation observed during pneumococcal keratitis [38]. Studies with strains lacking PLY have shown reduced virulence when compared to the parent strain in the rabbit keratitis model [31, 35, 38]. Pneumolysin appears to perform its dual roles of cytolytic activity and elicitation of inflammation during keratitis. First, PLY binds to lipid rafts in the corneal epithelial

cell membrane prior to subunit oligomerization and pore formation, resulting in host cell lysis [34]. Secondly, PLY elicits increased infiltration of neutrophils into the cornea as evidenced by histopathology of corneas infected with wild type bacteria compared to PLY-deficient bacteria [32, 91]. These findings indicated that much of the damage caused during keratitis likely results from both direct corneal cell death by PLY and immune-derived damage from proinflammatory signaling in response to PLY. While capsule does not seem to play a significant role in the progression of keratitis, PLY is a key virulence factor in the devastation caused to the corneal cells both *in vivo* and *in vitro* [9, 31, 32].

2.3. Endophthalmitis. Though keratitis and conjunctivitis have a higher incidence than endophthalmitis, these infections are usually much less severe and easier to treat and carry a lower risk of vision loss or enucleation [62, 63, 66, 82, 92–95]. Approximately 0.05% of patients undergoing intraocular surgery develop bacterial endophthalmitis, resulting in a relatively low incidence of disease [96, 97]. The infection most commonly occurs after cataract removal, intravitreal injections, or a penetrating eye trauma [96–100]. The three main pathogens that cause bacterial endophthalmitis are coagulase-negative *Staphylococcus* (70%), *Staphylococcus aureus* (10%), and streptococcal species (9%) [100–103]. But, streptococcal species were three times as likely to be the cause of bacterial endophthalmitis in patients receiving intravitreal injections from ophthalmologists who did not wear facial masks [104].

The polysaccharide capsule is necessary for full virulence in pneumococcal endophthalmitis [61, 105]. In a study comparing a capsule-deficient isogenic mutant of a *S. pneumoniae* clinical isolate to the parent strain in a rabbit endophthalmitis model, both animal groups suffered from vitreal infections [105]. However, rabbits infected with parent strain exhibited significantly higher biomicroscopy scores at 24 and 48 hours, indicating a more severe disease [105]. The same study showed significantly more bacteria were recovered from the eyes infected with the parent strain as well. In a separate study, the same group investigated the benefits of passive immunization with Pneumovax®23 (one of the currently approved pneumococcal capsule-based vaccines) to prevent infection due to prevalence of encapsulated pneumococcus causing endophthalmitis. While the results did show less severe symptoms and lower biomicroscopy scores for rabbits immunized with Pneumovax®23, bacteria were still able to grow and subsequently cause disease [36].

Similarly, an intraocular infection with a PLY-deficient strain also resulted in less tissue damage and lower biomicroscopy scores [25, 106]. In a study comparing eye infections with strains that produce different amounts of pneumococcal toxin, strains with higher PLY activity caused more inflammation and tissue damage [107]. Interestingly, PLY by itself in the vitreous humor can cause the same tissue damage and histopathology seen in an infection with the bacteria [106]. A 2010 study by Sanders *et al.* immunized rabbits with antiserum to PLY as an attempt to prevent damage accrued by the cytolytic toxin. The immunized rabbits had significantly lower biomicroscopy score at 24 and 48 hours, and less retinal

TABLE 1: Virulence factor requirement during different ocular infectious diseases.

<u>Virulence factor</u>	<u>Conjunctivitis</u> (reference)	<u>Keratitis</u> (reference)	<u>Endophthalmitis</u> (reference)
Polysaccharide capsule	dispensable [7, 15, 64, 68, 112]	dispensable [7, 9]	necessary [105]
Pneumolysin (PLY)	Unknown	necessary [9, 32, 34]	necessary [25, 36, 37, 106]
Neuraminidase	necessary [7, 68]	necessary [7, 61]	unknown [108]
Zinc metalloproteinase C (ZmpC)	necessary [54, 55]	necessary [55]	unknown

damage; however, there was not a significant difference in bacterial burden recovered from the vitreous [37].

The deletion of neuraminidase genes, on the other hand, has shown a very different effect during endophthalmitis. NanA deficient, NanB deficient, and NanAB deficient strains were tested in the rabbit endophthalmitis model [108]. The loss of the neuraminidases did not significantly decrease the severity of disease, but rather eyes infected with the mutants had significantly higher biomicroscopy scores indicating a more severe disease [108].

Aggressive treatments for streptococcal endophthalmitis infections include removal of the vitreous humor (vitrectomy) and intravitreal injections of combinations of antibiotics including vancomycin and either ceftazidime or amikacin [99, 109]. Patients receiving intraocular injections of vancomycin unfortunately are at risk for developing hemorrhagic occlusive retinal vasculitis (HORV), which can also lead to significantly decreased visual acuity or enucleation [110]. HORV is typically caused by a delayed onset hypersensitivity to vancomycin, occurring approximately 8 days after administration [110]. Topical antibiotic drops also have no prophylactic effect on bacterial endophthalmitis [111]. Both disease and treatment cause corrected visual acuity outcomes of 20/200 to 20/70 in affected eyes; therefore, the need to develop better endophthalmitis therapies is vital [110, 111].

3. Future Perspectives

Researchers have extensively studied many of the pneumococcal virulence factors in systemic disease models, but we know far less about the impact in the ocular environment, as outlined in Table 1.

For instance, a literature search for PLY knockout studies in a conjunctivitis model yields no results. Nonencapsulated strains are the predominant cause of pneumococcal conjunctivitis, which indicates that one or more factors other than capsule is involved during infection, and PLY is a prime candidate given its involvement in keratitis and endophthalmitis [7, 15, 16, 64]. Therefore, without PLY to initiate an inflammatory cytokine cascade [32, 106, 113], the damage is likely to be less severe when compared to the parent strain. As seen in a keratitis study, topically applied cholesterol negates much of the damage caused by PLY, due to cholesterol's ability to inactivate PLY [38]. The same treatment approach could be investigated for conjunctivitis to spare overuse of antibiotics.

S. pneumoniae also has three other zinc metalloproteinases, IgA1, ZmpB, and ZmpD [48, 114]; yet, at the time

this review was written, none have been studied in the context of ocular diseases. ZmpB induces a TNF- α inflammatory response, similar to PLY [113], when *S. pneumoniae* infects the lower respiratory tract of mice [53]. TNF- α not only changes the morphology, but also damages the cytoplasm of rabbit corneal cells [115]. Mice infected intranasally with a strain lacking ZmpB had significantly lower cytokine levels than mice infected with the wild type strain [53]. Therefore, it is possible that ZmpB might play a major role in both keratitis and endophthalmitis by initiating the host inflammatory cascade.

In conjunctivitis and keratitis, the presence of pneumococcal neuraminidases leads to more severe disease [7, 15]; the opposite is true in the intraocular environment. Only one study has analyzed the pathogenicity potential of neuraminidases in endophthalmitis [108]. Increased expression of *nanA* and *nanB* were seen during pneumococcal endophthalmitis; however, a deletion of *nanA*, *nanB*, or both caused a significant increase in biomicroscopy scores [108]. Interestingly, capsule gene expression was also decreased [108] even though the capsule is required for full virulence during endophthalmitis [105]. One possibility of explaining these findings is that neuraminidase activity and capsule expression are coordinately regulated and deletion of one or the other results in differential pathogenic effects. For conjunctivitis, deletion of capsule results in increased neuraminidase production [7]. For endophthalmitis, deletion of neuraminidase and the resulting decrease in capsule expression might involve an alternate mechanism of regulation with a different effect than that from complete deletion of the capsule locus.

Another aspect of pneumococcal ocular infections that we know very little about is impact of the available nutrients. The intraocular environment provides an ideal niche for bacterial growth. *S. pneumoniae* has been shown to proliferate to 10^9 CFU/mL in rabbit vitreous [105], indicating an abundance of nutrients. The nutrients in the vitreous humor as well as the metabolic mechanisms that allow *S. pneumoniae* to propagate to such high numbers in the ocular environment remain unknown. *S. pneumoniae* is able to metabolize over 30 carbon sources *in vitro* [116], but prefers glucose as a carbon source [117–120]. Glucose is readily available in the intraocular environment, and in concentrations that mimic those found in blood [121]. However, one study showed that an abundance of glucose made no significant difference on the number of bacteria recovered from an endophthalmitis infection by utilizing insulin dependent diabetic rabbits [122]. Future investigations should focus on resolving this discrepancy.

4. Conclusion

While *S. pneumoniae* remains one of the leading causes of serious systemic diseases such as bacterial pneumonia and meningitis, it is also a major cause of concern in the realm of ocular infections. *S. pneumoniae* remains one of the top causative bacterial pathogens for all three types of ocular infections described in this review. Conjunctivitis is treatable with topical antibiotics, keratitis is treatable but can lead to corneal scarring, and endophthalmitis more often than not leads to severe vision loss and possible enucleation. Though two pneumococcal vaccines exist for the prevention of nonocular diseases, they do little to fully prevent ocular infections.

This pathogen has several virulence factors that wreak havoc on the conjunctiva, cornea, and intraocular system. The polysaccharide capsule allows the bacterium to evade the complement system. PLY mediates an inflammatory cascade that can be just as damaging, if not more so, than the bacterium itself. *S. pneumoniae* also possess three neuraminidases (NanA, NanB, and NanAB) that play a role adhesion and subsequently colonization. The metalloproteinase ZmpC removes crucial glycoproteins that are necessary for the recruitment of MMP-9, an essential metalloprotease for wound healing.

A better picture of pneumococcal virulence factors in previously unexplored ocular infection types would lead to a broader knowledge of their roles in pathogenesis. Understanding the nutritional landscape of the intraocular environment and pneumococcal metabolism could reveal novel virulence mechanisms. Most importantly, more knowledge about how the pneumococcus causes ocular infections and damage to the eye could potentially lead to sight-saving drug discoveries. Development of new therapeutics is especially important for endophthalmitis because one of the most used treatment options can, unfortunately, lead to ocular damage and loss of sight.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Acknowledgments

The authors would like to thank Dr. Justine L. Dees for her instrumental contribution in the construction and editing of the above review.

References

- [1] F. A. Loda, A. M. Collier, W. P. Glezen, K. Strangert, W. A. Clyde Jr., and F. W. Denny, "Occurrence of Diplococcus pneumoniae in the upper respiratory tract of children," *Journal of Pediatrics*, vol. 87, no. 6, pp. 1087–1093, 1975.
- [2] J. A. Thanassi, S. L. Hartman-Neumann, T. J. Dougherty, B. A. Dougherty, and M. J. Pucci, "Identification of 113 conserved essential genes using a high-throughput gene disruption system in *Streptococcus pneumoniae*," *Nucleic Acids Research*, vol. 30, no. 14, pp. 3152–3162, 2002.
- [3] Center for Disease Control and Prevention, *Prevention of pneumococcal disease: Recommendations of the advisory committee on immunization practices (ACIP)*, 1997.
- [4] M. Kilian, D. R. Riley, A. Jensen, H. Brüggemann, and H. Tettelin, "Parallel evolution of *Streptococcus pneumoniae* and *Streptococcus mitis* to pathogenic and mutualistic lifestyles," *mBio*, vol. 5, no. 4, pp. e01490–e015014, 2014.
- [5] D. Y. Kunimoto, S. Sharma, M. K. Ready et al., "Microbial keratitis in children," *Ophthalmology*, vol. 105, no. 2, pp. 252–257, 1998.
- [6] Q. C. Moore III, C. C. McCormick, E. W. Norcross et al., "Development of a streptococcus pneumoniae keratitis model in mice," *Ophthalmic Research*, vol. 42, no. 3, pp. 141–146, 2009.
- [7] E. W. Norcross, N. A. Tullos, S. D. Taylor, M. E. Sanders, and M. E. Marquart, "Assessment of streptococcus pneumoniae capsule in conjunctivitis and keratitis in vivo neuraminidase activity increases in nonencapsulated pneumococci following conjunctival infection," *Current Eye Research*, vol. 35, no. 9, pp. 787–798, 2010.
- [8] P. Asbell and S. Stenson, "Ulcerative Keratitis: Survey of 30 Years' Laboratory Experience," *JAMA Ophthalmology*, vol. 100, no. 1, pp. 77–80, 1982.
- [9] J. M. Reed, R. J. O'Callaghan, D. O. Girgis, C. C. McCormick, A. R. Caballero, and M. E. Marquart, "Ocular virulence of capsule-deficient *Streptococcus pneumoniae* in a rabbit keratitis model," *Investigative Ophthalmology & Visual Science*, vol. 46, no. 2, p. 604, 2005.
- [10] M. J. Jedrzejewski, "Pneumococcal virulence factors: Structure and function," *Microbiology and Molecular Biology Reviews*, vol. 65, no. 2, pp. 187–207, 2001.
- [11] T. J. Mitchell, P. W. Andrew, F. K. Saunders, A. N. Smith, and G. J. Boulnois, "Complement activation and antibody binding by pneumolysin via a region of the toxin homologous to a human acute-phase protein," *Molecular Microbiology*, vol. 5, no. 8, pp. 1883–1888, 1991.
- [12] J. Li, A. J. Szalai, S. K. Hollingshead, M. H. Nahm, and D. E. Briles, "Antibody to the type 3 capsule facilitates immune adherence of pneumococci to erythrocytes and augments their transfer to macrophages," *Infection and Immunity*, vol. 77, no. 1, pp. 464–471, 2009.
- [13] J. Yuste, A. Sen, L. Truedsson et al., "Impaired opsonization with C3b and phagocytosis of *Streptococcus pneumoniae* in sera from subjects with defects in the classical complement pathway," *Infection and Immunity*, vol. 76, no. 8, pp. 3761–3770, 2008.
- [14] C. Feldman and R. Anderson, "Review: Current and new generation pneumococcal vaccines," *The Journal of Infection*, vol. 69, no. 4, pp. 309–325, 2014.
- [15] M. D. Valentino, A. M. McGuire, J. W. Rosch et al., "Unencapsulated *Streptococcus pneumoniae* from conjunctivitis encode variant traits and belong to a distinct phylogenetic cluster," *Nature Communications*, vol. 5, article no. 5411, 2014.
- [16] N. F. Crum, C. P. Barrozo, F. A. Chapman, M. A. K. Ryan, and K. L. Russell, "An outbreak of conjunctivitis due to a novel unencapsulated *Streptococcus pneumoniae* among military trainees," *Clinical Infectious Diseases*, vol. 39, no. 8, pp. 1148–1154, 2004.
- [17] L. J. Hathaway, P. S. Meier, P. Bättig, S. Aebi, and K. Mühlemann, "A homologue of *aliB* is found in the capsule region of nonencapsulated *Streptococcus pneumoniae*," *Journal of Bacteriology*, vol. 186, no. 12, pp. 3721–3729, 2004.
- [18] S. J. Salter, J. Hinds, K. A. Gould et al., "Variation at the capsule locus, *cps*, of mistyped and non-typable *Streptococcus*

- pneumoniae isolates," *Microbiology (United Kingdom)*, vol. 158, no. 6, pp. 1560–1569, 2012.
- [19] I. H. Park, K.-H. Kim, A. L. Andrade, D. E. Briles, L. S. McDaniel, and M. H. Nahma, "Nontypeable pneumococci can be divided into multiple cps types, including one type expressing the novel gene *pspK*," *mBio*, vol. 3, no. 3, Article ID e00035-12, 2012.
- [20] L. E. Keller, C. V. Jones, J. A. Thornton et al., "PspK of Streptococcus pneumoniae increases adherence to epithelial cells and enhances nasopharyngeal colonization," *Infection and Immunity*, vol. 81, no. 1, pp. 173–181, 2013.
- [21] W. F. Goebel and O. T. Avery, "A Study of Pneumococcus Autolysis," *The Journal of Experimental Medicine*, vol. 49, no. 2, pp. 267–286, 1929.
- [22] P. Mellroth, R. Daniels, A. Eberhardt et al., "LytA, major autolysin of Streptococcus pneumoniae, requires access to nascent peptidoglycan," *The Journal of Biological Chemistry*, vol. 287, no. 14, pp. 11018–11029, 2012.
- [23] L. V. Howard and H. Gooder, "Specificity of the autolysin of Streptococcus (Diplococcus) pneumoniae," *Journal of Bacteriology*, vol. 117, no. 2, pp. 796–804, 1974.
- [24] A. M. Berry and J. C. Paton, "Additive attenuation of virulence of Streptococcus pneumoniae by mutation of the genes encoding pneumolysin and other putative pneumococcal virulence proteins," *Infection and Immunity*, vol. 68, no. 1, pp. 133–140, 2000.
- [25] E. W. M. Ng, J. Ricardo Costa, N. Samiy et al., "Contribution of pneumolysin and autolysin to the pathogenesis of experimental pneumococcal endophthalmitis," *Retina*, vol. 22, no. 5, pp. 622–632, 2002.
- [26] J. R. Canvin, A. P. Marvin, M. Sivakumaran et al., "The Role of Pneumolysin and Autolysin in the Pathology of Pneumonia and Septicemia in Mice Infected with a Type 2 Pneumococcus," *The Journal of Infectious Diseases*, vol. 172, no. 1, pp. 119–123, 1995.
- [27] R. A. Hirst, B. Gosai, A. Rutman et al., "Streptococcus pneumoniae deficient in pneumolysin or autolysin has reduced virulence in meningitis," *The Journal of Infectious Diseases*, vol. 197, no. 5, pp. 744–751, 2008.
- [28] V. Eldholm, O. Johnsborg, K. Haugen, H. S. Ohnstad, and L. S. Havastein, "Fratricide in Streptococcus pneumoniae: Contributions and role of the cell wall hydrolases CbpD, LytA and LytC," *Microbiology*, vol. 155, no. 7, pp. 2223–2234, 2009.
- [29] A. Martner, S. Skovbjerg, J. C. Paton, and A. E. Wold, "Streptococcus pneumoniae autolysin prevents phagocytosis and production of phagocyte-activating cytokines," *Infection and Immunity*, vol. 77, no. 9, pp. 3826–3837, 2009.
- [30] A. Martner, C. Dahlgren, J. C. Paton, and A. E. Wold, "Pneumolysin released during Streptococcus pneumoniae autolysis is a potent activator of intracellular oxygen radical production in neutrophils," *Infection and Immunity*, vol. 76, no. 9, pp. 4079–4087, 2008.
- [31] M. K. Johnson, J. A. Hobden, M. Hagenah, R. J. O'callaghan, J. M. Hill, and S. Chen, "The role of pneumolysin in ocular infections with streptococcus pneumoniae," *Current Eye Research*, vol. 9, no. 11, pp. 1107–1114, 1990.
- [32] M. K. Johnson, J. A. Hobden, R. J. O'Callaghan, and J. M. Hill, "Confirmation of the role of pneumolysin in ocular infections with streptococcus pneumoniae," *Current Eye Research*, vol. 11, no. 12, pp. 1221–1225, 1992.
- [33] J. Thornton and L. S. McDaniel, "THP-1 monocytes up-regulate intercellular adhesion molecule 1 in response to pneumolysin from Streptococcus pneumoniae," *Infection and Immunity*, vol. 73, no. 10, pp. 6493–6498, 2005.
- [34] S. D. Taylor, M. E. Sanders, N. A. Tullis et al., "The Cholesterol-Dependent Cytolysin Pneumolysin from Streptococcus pneumoniae Binds to Lipid Raft Microdomains in Human Corneal Epithelial Cells," *PLoS ONE*, vol. 8, no. 4, p. e61300, 2013.
- [35] E. W. Norcross, M. E. Sanders, Q. C. Moore, and M. E. Marquart, "Pathogenesis of a clinical ocular strain of Streptococcus pneumoniae and the interaction of pneumolysin with corneal cells," *Journal of Bacteriology & Parasitology*, vol. 2, no. 2, p. 108, 2011.
- [36] M. E. Sanders, S. Taylor, N. Tullis et al., "Passive immunization with Pneumovax® 23 and pneumolysin in combination with vancomycin for pneumococcal endophthalmitis," *BMC Ophthalmology*, vol. 13, no. 1, p. 8, 2013.
- [37] M. E. Sanders, E. W. Norcross, Q. C. Moore, J. Fratkin, H. Thompson, and M. E. Marquart, "Immunization with pneumolysin protects against both retinal and global damage caused by streptococcus pneumoniae endophthalmitis," *Journal of Ocular Pharmacology and Therapeutics*, vol. 26, no. 6, pp. 571–577, 2010.
- [38] M. E. Marquart, K. S. Monds, C. C. McCormick et al., "Cholesterol as treatment for pneumococcal keratitis: Cholesterol-specific inhibition of pneumolysin in the cornea," *Investigative Ophthalmology & Visual Science*, vol. 48, no. 6, pp. 2661–2666, 2007.
- [39] R. K. Tweten, "Cholesterol-dependent cytolysins, a family of versatile pore-forming toxins," *Infection and Immunity*, vol. 73, no. 10, pp. 6199–6209, 2005.
- [40] J. C. Paton, B. Rowan Kelly, and A. Ferrante, "Activation of human complement by the pneumococcal toxin pneumolysin," *Infection and Immunity*, vol. 43, no. 3, pp. 1085–1087, 1984.
- [41] J. D. Langereis and M. I. de Jonge, "Nonencapsulated Streptococcus pneumoniae, vaccination as a measure to interfere with horizontal gene transfer," *Virulence*, vol. 8, no. 6, pp. 637–639, 2017.
- [42] S. Manco, F. Herson, H. Yesilkaya, J. C. Paton, P. W. Andrew, and A. Kadioglu, "Pneumococcal neuraminidases A and B both have essential roles during infection of the respiratory tract and sepsis," *Infection and Immunity*, vol. 74, no. 7, pp. 4014–4020, 2006.
- [43] R. T. Kelly, S. Farmer, and D. Greiff, "Neuraminidase activities of clinical isolates of Diplococcus pneumoniae," *Journal of Bacteriology*, vol. 94, no. 1, pp. 272–273, 1967.
- [44] R. D. O'Toole, L. Goode, and C. Howe, "Neuraminidase activity in bacterial meningitis," *The Journal of Clinical Investigation*, vol. 50, no. 5, pp. 979–985, 1971.
- [45] G. Kreil, "Hyaluronidases—a group of neglected enzymes," *Protein Science*, vol. 4, no. 9, pp. 1666–1669, 1995.
- [46] F. Duran-Reynal, "Studies on a certain spreading factor existing in bacteria and its significance for bacterial invasiveness," *The Journal of Experimental Medicine*, vol. 58, no. 2, pp. 161–181, 1933.
- [47] D. G. Pritchard, B. Lin, T. R. Willingham, and J. R. Baker, "Characterization of the group B Streptococcal hyaluronate lyase," *Archives of Biochemistry and Biophysics*, vol. 315, no. 2, pp. 431–437, 1994.
- [48] M. Bek-Thomsen, K. Poulsen, and M. Kilian, "Occurrence and evolution of the paralogous zinc metalloproteases IgA1 protease, ZmpB, ZmpC, and ZmpD in streptococcus pneumoniae and related commensal species," *mBio*, vol. 3, no. 5, 2012.
- [49] A. G. Plaut, "The IgA1 proteases of pathogenic bacteria," *Annual Review of Microbiology*, vol. 37, pp. 603–622, 1983.

- [50] J. N. Weiser, D. Bae, C. Fasching, R. W. Scamurra, A. J. Ratner, and E. N. Janoff, "Antibody-enhanced pneumococcal adherence requires IgA1 protease," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 100, no. 7, pp. 4215–4220, 2003.
- [51] Y. Gong, W. Xu, Y. Cui et al., "Immunization with a ZmpB-based protein vaccine could protect against pneumococcal diseases in mice," *Infection and Immunity*, vol. 79, no. 2, pp. 867–878, 2011.
- [52] R. Camilli, E. Pettini, M. Del Grosso, G. Pozzi, A. Pantosti, and M. R. Oggioni, "Zinc metalloproteinase genes in clinical isolates of *Streptococcus pneumoniae*: Association of the full array with a clonal cluster comprising serotypes 8 and 11A," *Microbiology*, vol. 152, no. 2, pp. 313–321, 2006.
- [53] C. E. Blue, G. K. Paterson, A. R. Kerr, M. Bergé, J. P. Claverys, and T. J. Mitchell, "ZmpB, a novel virulence factor of *Streptococcus pneumoniae* that induces tumor necrosis factor alpha production in the respiratory tract," *Infection and Immunity*, vol. 71, no. 9, pp. 4925–4935, 2003.
- [54] M. R. Oggioni, G. Memmi, T. Maggi, D. Chiavolini, F. Iannelli, and G. Pozzi, "Pneumococcal zinc metalloproteinase ZmpC cleaves human matrix metalloproteinase 9 and is a virulence factor in experimental pneumonia," *Molecular Microbiology*, vol. 49, no. 3, pp. 795–805, 2003.
- [55] B. Govindarajan, B. B. Menon, S. Spurr-Michaud et al., "A metalloproteinase secreted by *Streptococcus pneumoniae* removes membrane mucin MUC16 from the epithelial glycocalyx barrier," *PLoS ONE*, vol. 7, no. 3, p. e32418, 2012.
- [56] B. G. J. Surewaard, K. Trzciński, S. R. Jacobino et al., "Pneumococcal immune evasion: ZmpC inhibits neutrophil influx," *Cellular Microbiology*, vol. 15, no. 10, pp. 1753–1765, 2013.
- [57] A. Stadtmann, G. Germena, H. Block et al., "The PSGL-1-L-selectin signaling complex regulates neutrophil adhesion under flow," *The Journal of Experimental Medicine*, vol. 210, no. 11, pp. 2171–2180, 2013.
- [58] A. F. Smith and C. Waycaster, "Estimate of the direct and indirect annual cost of bacterial conjunctivitis in the United States," *BMC Ophthalmology*, vol. 9, no. 1, p. 13, 2009.
- [59] A. A. Azari and N. P. Barney, "Conjunctivitis: A systematic review of diagnosis and treatment," *Journal of the American Medical Association*, vol. 310, no. 16, pp. 1721–1729, 2013.
- [60] H. M. Leibowitz, "The red eye," *New England Journal of Medicine*, vol. 343, no. 5, pp. 345–351, 2000.
- [61] E. W. Norcross, M. E. Sanders, Q. C. Moore et al., "Active immunization with pneumolysin versus 23-valent polysaccharide vaccine for *Streptococcus pneumoniae* keratitis," *Investigative ophthalmology & visual science*, vol. 52, no. 12, pp. 9232–9243, 2011.
- [62] J. Epling, "Bacterial conjunctivitis," *BMJ Clinical Evidence*, vol. 2012, 2012.
- [63] A. B. Tarabishy and B. H. Jeng, "Bacteria conjunctivitis: A review for internists," *Cleveland Clinic Journal of Medicine*, vol. 75, no. 7, pp. 507–512, 2008.
- [64] J. M. Buck, C. Lexau, M. Shapiro et al., "A community outbreak of conjunctivitis caused by nontypeable *Streptococcus pneumoniae* in Minnesota," *The Pediatric Infectious Disease Journal*, vol. 25, no. 10, pp. 906–911, 2006.
- [65] A. Sheikh, B. Hurwitz, C. P. van Schayck, S. McLean, and U. Nurmatov, "Antibiotics versus placebo for acute bacterial conjunctivitis," *Cochrane Database of Systematic Reviews*, 2012.
- [66] T. J. Liesegang, "Bacterial keratitis," *Infectious Disease Clinics of North America*, vol. 6, no. 4, pp. 815–829, 1992.
- [67] I. Antic, K. M. Brothers, M. Stolzer et al., "Gene acquisition by a distinct phyletic group within *Streptococcus pneumoniae* promotes adhesion to the ocular epithelium," *mSphere*, vol. 2, no. 5, 2017.
- [68] Y. M. Williamson, R. Gowrisankar, D. L. Longo et al., "Adherence of nontypeable *Streptococcus pneumoniae* to human conjunctival epithelial cells," *Microbial Pathogenesis*, vol. 44, no. 3, pp. 175–185, 2008.
- [69] C. Dixit, L. E. Keller, J. L. Bradshaw, D. A. Robinson, E. Swiatlo, and L. S. McDaniel, "Nonencapsulated *Streptococcus pneumoniae* as a cause of chronic adenoiditis," *IDCases*, vol. 4, pp. 56–58, 2016.
- [70] J. L. Bradshaw, H. R. Pipkins, L. E. Keller, J. K. Pendarvis, and L. S. McDaniel, "Mucosal infections and invasive potential of nonencapsulated streptococcus pneumoniae are enhanced by oligopeptide binding proteins AliC and AliD," *mBio*, vol. 9, no. 1, Article ID e02097-17, 2018.
- [71] P. K. Singh and M. A. Hollingsworth, "Cell surface-associated mucins in signal transduction," *Trends in Cell Biology*, vol. 16, no. 9, pp. 467–476, 2006.
- [72] S. K. Linden, P. Sutton, N. G. Karlsson, V. Korolik, and M. A. McGuckin, "Mucins in the mucosal barrier to infection," *Mucosal Immunology*, vol. 1, no. 3, pp. 183–197, 2008.
- [73] T. D. Blalock, S. J. Spurr-Michaud, A. S. Tisdale et al., "Functions of MUC16 in corneal epithelial cells," *Investigative Ophthalmology & Visual Science*, vol. 48, no. 10, pp. 4509–4518, 2007.
- [74] P. Argüeso, A. Tisdale, S. Spurr-Michaud, M. Sumiyoshi, and I. K. Gipson, "Mucin characteristics of human corneal-limbal epithelial cells that exclude the rose bengal anionic dye," *Investigative Ophthalmology & Visual Science*, vol. 47, no. 1, pp. 113–119, 2006.
- [75] A.-C. Buisson, J.-M. Zahm, M. Polette et al., "Gelatinase B is involved in the in vitro wound repair of human respiratory epithelium," *Journal of Cellular Physiology*, vol. 166, no. 2, pp. 413–426, 1996.
- [76] Y.-N. Yang, F. Wang, W. Zhou, Z.-Q. Wu, and Y.-Q. Xing, "TNF- α stimulates MMP-2 and MMP-9 activities in human corneal epithelial cells via the activation of FAK/ERK signaling," *Ophthalmic Research*, vol. 48, no. 4, pp. 165–170, 2012.
- [77] G. Rajashekhar, M. Shivanna, U. B. Kompella, Y. Wang, and S. P. Srinivas, "Role of MMP-9 in the breakdown of barrier integrity of the corneal endothelium in response to TNF- α ," *Experimental Eye Research*, vol. 122, no. 5, pp. 77–85, 2014.
- [78] H. C. Tseng, I. T. Lee, C. C. Lin et al., "Correction: IL-1 β Promotes Corneal Epithelial Cell Migration by Increasing MMP-9 Expression through NF- κ B- and AP-1-Dependent Pathways," *PLoS ONE*, vol. 8, no. 3, 2013.
- [79] J. K. G. Dart, F. Stapleton, D. Minassian, and J. K. G. Dart, "Contact lenses and other risk factors in microbial keratitis," *The Lancet*, vol. 338, no. 8768, pp. 650–653, 1991.
- [80] D. C. Musch, A. Sugar, and R. F. Meyer, "Demographic and Pre-disposing Factors in Corneal Ulceration," *JAMA Ophthalmology*, vol. 101, no. 10, pp. 1545–1548, 1983.
- [81] A. I. Miedziak, M. R. Miller, C. J. Rapuano, P. R. Laibson, and E. J. Cohen, "Risk factors in microbial keratitis leading to penetrating keratoplasty," *Ophthalmology*, vol. 106, no. 6, pp. 1166–1171, 1999.
- [82] A. Al-Mujaini, N. Al-Kharusi, A. Thakral, and U. K. Wali, "Bacterial keratitis: Perspective on epidemiology, Clinico-Pathogenesis, diagnosis and treatment," *Sultan Qaboos University Medical Journal*, vol. 9, no. 2, pp. 184–195, 2009.

- [83] J. Kaliyamurthy, C. M. Kalavathy, P. Parmar, C. A. Nelson Jesudasan, and P. A. Thomas, "Spectrum of bacterial keratitis at a tertiary eye care centre in India," *BioMed Research International*, vol. 2013, Article ID 181564, 2013.
- [84] M. E. Marquart and R. J. O'Callaghan, "Infectious keratitis: Secreted bacterial proteins that mediate corneal damage," *Journal of Ophthalmology*, vol. 2013, Article ID 369094, 2013.
- [85] J. Mascarenhas, P. Lalitha, N. V. Prajna et al., "Acanthamoeba, fungal, and bacterial keratitis: A comparison of risk factors and clinical features," *American Journal of Ophthalmology*, vol. 157, no. 1, pp. 56–62, 2014.
- [86] J. Mascarenhas, M. Srinivasan, M. Chen et al., "Differentiation of etiologic agents of bacterial keratitis from presentation characteristics," *International Ophthalmology*, vol. 32, no. 6, pp. 531–538, 2012.
- [87] A. Austin, T. Lietman, and J. Rose-Nussbaumer, "Update on the Management of Infectious Keratitis," *Ophthalmology*, vol. 124, no. 11, pp. 1678–1689, 2017.
- [88] C. R. Henry, H. W. Flynn Jr., D. Miller, A. C. Scheffler, R. K. Forster, and E. C. Alfonso, "Delayed-onset endophthalmitis associated with corneal suture infections," *Journal of Ophthalmic Inflammation and Infection*, vol. 3, no. 1, p. 51, 2013.
- [89] A. Austin, J. Schallhorn, M. Geske, M. Mannis, T. Lietman, and J. Rose-Nussbaumer, "Empirical treatment of bacterial keratitis: an international survey of corneal specialists," *BMJ Open Ophthalmology*, vol. 2, no. 1, p. e000047, 2017.
- [90] N. A. Tullios, H. W. Thompson, S. D. Taylor et al., "Modulation of immune signaling, bacterial clearance, and corneal integrity by toll-like receptors during streptococcus pneumoniae keratitis," *Current Eye Research*, vol. 38, no. 10, pp. 1036–1048, 2013.
- [91] S. N. Green, M. Sanders, Q. C. Moore et al., "Protection from Streptococcus pneumoniae keratitis by passive immunization with pneumolysin antiserum," *Investigative Ophthalmology & Visual Science*, vol. 49, no. 1, pp. 290–294, 2008.
- [92] C. R. Henry, H. W. Flynn Jr., D. Miller, R. K. Forster, and E. C. Alfonso, "Infectious keratitis progressing to endophthalmitis: A 15-year study of microbiology, associated factors, and clinical outcomes," *Ophthalmology*, vol. 119, no. 12, pp. 2443–2449, 2012.
- [93] S. A. Alfonso, J. D. Fawley, and X. A. Lu, "Conjunctivitis," *Primary Care—Clinics in Office Practice*, vol. 42, no. 3, pp. 325–345, 2015.
- [94] R. K. Forster, I. G. Zachary, A. J. Cottingham, and E. W. Norton, "Further Observations on the Diagnosis, Cause, and Treatment of Endophthalmitis," *American Journal of Ophthalmology*, vol. 81, no. 1, pp. 52–56, 1976.
- [95] P. Meier and P. Wiedemann, "Endophthalmitis—clinical picture, therapy and prevention," *Klinische Monatsblätter für Augenheilkunde*, vol. 210, no. 4, pp. 175–191, 1997.
- [96] M. Lundström, G. Wejde, U. Stenevi, W. Thorburn, and P. Montan, "Endophthalmitis after Cataract Surgery. A Nationwide Prospective Study Evaluating Incidence in Relation to Incision Type and Location," *Ophthalmology*, vol. 114, no. 5, pp. 866–870, 2007.
- [97] M. M. Sachdeva, A. Moshiri, H. A. Leder, and A. W. Scott, "Endophthalmitis following intravitreal injection of anti-VEGF agents: long-term outcomes and the identification of unusual micro-organisms," *Journal of Ophthalmic Inflammation and Infection*, vol. 6, no. 1, p. 2, 2016.
- [98] S. L. Tyson, R. Bailey, J. S. Roman, T. Zhan, L. A. Hark, and J. A. Haller, "Clinical outcomes after injection of a compounded pharmaceutical for prophylaxis after cataract surgery: A large-scale review," *Current Opinion in Ophthalmology*, vol. 28, no. 1, pp. 73–80, 2017.
- [99] S. G. Schwartz, H. W. Flynn, T. Das, and W. F. Mieler, "Ocular infection: Endophthalmitis," *Developments in Ophthalmology*, vol. 55, pp. 176–188, 2015.
- [100] M. L. Durand, "Bacterial and fungal endophthalmitis," *Clinical Microbiology Reviews*, vol. 30, no. 3, pp. 597–613, 2017.
- [101] D. Y. Kunimoto, T. Das, S. Sharma et al., "icrobiologic spectrum and susceptibility of isolates: part I. Postoperative endophthalmitis. Endophthalmitis Research Group," *American Journal of Ophthalmology*, vol. 128, no. 2, pp. 240–242, 1999.
- [102] T. Leng, D. Miller, H. W. Flynn Jr., D. J. Jacobs, and S. J. Gedde, "Delayed-onset bleb-associated endophthalmitis (1996-2008)," *Retina*, vol. 31, no. 2, pp. 344–352, 2011.
- [103] Endophthalmitis Vitrectomy Study Group, "Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis," *Archives of ophthalmology*, vol. 113, no. 12, pp. 1479–1496, 1995.
- [104] C. A. McCannel, "Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: Causative organisms and possible prevention strategies," *Retina*, vol. 31, no. 4, pp. 654–661, 2011.
- [105] M. E. Sanders, E. W. Norcross, Z. M. Robertson, Q. C. Moore III, J. Fratkin, and M. E. Marquart, "The Streptococcus pneumoniae capsule is required for full virulence in pneumococcal endophthalmitis," *Investigative Ophthalmology & Visual Science*, vol. 52, no. 2, pp. 865–872, 2011.
- [106] E. W. M. Ng, N. Samiy, J. B. Rubins et al., "Implication of pneumolysin as a virulence factor in Streptococcus pneumoniae endophthalmitis," *Retina*, vol. 17, no. 6, pp. 521–529, 1997.
- [107] M. E. Sanders, E. W. Norcross, Q. C. Moore et al., "A comparison of pneumolysin activity and concentration in vitro and in vivo in a rabbit endophthalmitis model," *Clinical Ophthalmology*, vol. 2, no. 4, pp. 793–800, 2008.
- [108] J. A. Thornton, N. A. Tullios, M. E. Sanders et al., "Differential bacterial gene expression during experimental pneumococcal endophthalmitis," *Ophthalmic Research*, vol. 53, no. 3, pp. 149–161, 2015.
- [109] M. C. Callegan, M. Engelbert, D. W. Parke, B. D. Jett, and M. S. Gilmore, "Bacterial endophthalmitis: epidemiology, therapeutics, and bacterium-host interactions," *Clinical Microbiology Reviews*, vol. 15, no. 1, pp. 111–124, 2002.
- [110] A. J. Witkin, D. F. Chang, J. M. Jumper et al., "Vancomycin-Associated Hemorrhagic Occlusive Retinal Vasculitis," *Ophthalmology*, vol. 124, no. 5, pp. 583–595, 2017.
- [111] A. E. Kuriyan, K. D. Weiss, H. W. Flynn et al., "Endophthalmitis caused by streptococcal species: clinical settings, microbiology, management, and outcomes," *American Journal of Ophthalmology*, vol. 157, no. 4, pp. 774–780, 2014.
- [112] J. M. Marimon, M. Ercibengoa, J. M. García-Arenzana, M. Alonso, and E. Pérez-Trallero, "Streptococcus pneumoniae ocular infections, prominent role of unencapsulated isolates in conjunctivitis," *Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases*, vol. 19, no. 7, pp. E298–E305, 2013.
- [113] S. Houldsworth, P. W. Andrew, and T. J. Mitchell, "Pneumolysin stimulates production of tumor necrosis factor alpha and interleukin-1 β by human mononuclear phagocytes," *Infection and Immunity*, vol. 62, no. 4, pp. 1501–1503, 1994.

- [114] D. Chiavolini, G. Memmi, T. Maggi, F. Iannelli, G. Pozzi, and M. R. Oggioni, "The three extra-cellular zinc metalloproteinases of *Streptococcus pneumoniae* have a different impact on virulence in mice," *BMC Microbiology*, vol. 3, article no. 1, p. 14, 2003.
- [115] Z.-Q. Wu, Z.-L. Zhang, S.-W. Nie, J. Yuan, and Y.-N. Yang, "Activity of matrix metalloproteinases 2 and 9 in cultured rabbit corneal epithelium cells stimulated by tumor necrosis factor alpha," *Genetics and Molecular Research*, vol. 14, no. 2, pp. 6360–6368, 2015.
- [116] C. M. Buckwalter and S. J. King, "Pneumococcal carbohydrate transport: Food for thought," *Trends in Microbiology*, vol. 20, no. 11, pp. 517–522, 2012.
- [117] S. M. Carvalho, T. G. Kloosterman, O. P. Kuipers, and A. R. Neves, "CcpA ensures optimal metabolic fitness of streptococcus pneumoniae," *PLoS ONE*, vol. 6, no. 10, p. e26707, 2011.
- [118] G. E. Kaufman and J. Yother, "CcpA-dependent and -independent control of beta-galactosidase expression in *Streptococcus pneumoniae* occurs via regulation of an upstream phosphotransferase system-encoding operon," *Journal of Bacteriology*, vol. 189, no. 14, pp. 5183–5192, 2007.
- [119] L. Paixão, J. Caldas, T. G. Kloosterman, O. P. Kuipers, S. Vinga, and A. R. Neves, "Transcriptional and metabolic effects of glucose on *Streptococcus pneumoniae* sugar metabolism," *Frontiers in Microbiology*, vol. 6, p. 1041, 2015.
- [120] A. Cochu, C. Vadeboncoeur, S. Moineau, and M. Frenette, "Genetic and biochemical characterization of the phosphoenolpyruvate:glucose/mannose phosphotransferase system of *Streptococcus thermophilus*," *Applied and Environmental Microbiology*, vol. 69, no. 9, pp. 5423–5432, 2003.
- [121] O. Lundquist and S. Österlin, "Glucose concentration in the vitreous of nondiabetic and diabetic human eyes," *Graefes Archive for Clinical and Experimental Ophthalmology*, vol. 32, no. 2, pp. 71–74, 1994.
- [122] A. H. Benton, L. K. Fulton, and M. E. Marquart, "Exogenous *Streptococcus pneumoniae* Endophthalmitis in Diabetic Rabbits," *Scientific Reports*, vol. 7, p. 46196, 2017.



Hindawi

Submit your manuscripts at
www.hindawi.com

